Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial
Last updated: 11:39 17 Sep 2026 EDT, First published: 09:39 17 Sep 2026 EDT
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has signed a Memorandum of Understanding with the King Abdullah International Medical Research Center (KAIMRC) and the Foundation for Neurologic Diseases to study its intranasal foralumab in combination with anti-CD20 therapy for multiple sclerosis patients.
The planned trial will target relapsing-remitting multiple sclerosis (RRMS) patients who respond poorly to anti-CD20 therapy alone, a shortfall that may stem from untreated neuroinflammation.
Foralumab, a fully human anti-CD3 monoclonal antibody, has shown reductions in neuroinflammation across three clinical studies to date.
KAIMRC, a translational research center under the Ministry of National Guard – Health Affairs affiliated with KSAU-HS that supports Saudi Vision 2030 and the National Biotechnology Strategy, is partnering with the Foundation for Neurologic Diseases, which specializes in neuroimmunology and multiple sclerosis research.
Ivor Elrifi, CEO of Tiziana, signed the MOU on the main stage of the Riyadh Global Medical Biotechnology Summit in Riyadh, Saudi Arabia, on September 16.
"This MOU marks an important step in fostering international scientific collaboration in neuroimmunology and immunomodulation research," Elrifi said.
According to Elrifi, the collaboration represents an additional multiple sclerosis indication beyond the company's ongoing non-active secondary progressive MS (na-SPMS) program, and does not change its efforts toward that program, where the Phase 2 trial remains blinded with results expected in October.
"Signing the agreement at RGMBS in Riyadh underscores the growing global interest in collaborative approaches to address these significant unmet medical needs," he said.
The news sent shares of Tiziana rocketing over 18% higher on Thursday morning.